Maike Zimmermann

Medicine · Health Sciences

13h-index636citations59works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Metal complexes synthesis and properties(20), DNA Repair Mechanisms(12), Cancer Treatment and Pharmacology(8), Cancer, Hypoxia, and Metabolism(7), Cancer, Lipids, and Metabolism(7)

Publications59 total

Concordance of Truvian’s Benchtop Blood Testing Platform to Central Laboratory Testing
2023Open Access
Supplementary Figure Legends from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Table S1 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Figure S2 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Supplementary Figure S1 from Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy
2023Open Access
Figure S1 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Figure S7 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Data from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Figure S6 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Figure S4 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Supplementary Data from Microdose-Induced Drug–DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice
2023Open Access
Data from Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy
2023Open Access
Table S1 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Figure S7 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Figure S4 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Supplementary Figure Legends from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Data from Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy
2023Open Access
Data from Microdose-Induced Drug–DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice
2023Open Access
Figure S5 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
2023Open Access
Data from Microdose-Induced Drug–DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Paul T. Henderson(35), Michael Malfatti(30), Kenneth W. Turteltaub(30), Chong-xian Pan(27), Hongyong Zhang(21), Susan Airhart(20), Tzu‐yin Lin(20), George D. Cimino(16), Sung Hee Hwang(16), Bruce D. Hammock(16), Ai‐Hong Ma(16), Fuli Wang(14), Weimin Yu(14), Daniel Zhu(14), Ralph W. de Vere White(14), Jianlin Yuan(13), Kurt Haack(9), Chong‐Xian Pan(8), Ralph de Vere White(8), Jun Yang(8)